BNTX vs INSM
BioNTech SE and Insmed Incorporated, both Healthcare
BioNTech SE is the larger company at $23B against $23B. Over the past year BNTX returned +0.8% against -30% for INSM. The RyuScore puts BNTX ahead, 34 against 18 out of 100.
| Figure | BNTX | INSM |
|---|---|---|
| Last close | $96.95 | $101 |
| Market cap | $23B | $23B |
| 1-year return | +0.8% | -30% |
| 5-year return | -71% | +269% |
| RyuScoresector-relative, 1–10 | 34/100 | 18/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BioNTech SE
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.